A comparison of short-term effects of intravitreal triamcinolone acetonide and bevacizumab on retinal vascular caliber in patients with diabetic macular edema

Basit Öğe Kaydı
dc.authorscopusid6506789098
dc.authorscopusid57215431649
dc.authorscopusid56007692400
dc.authorscopusid56008022700
dc.authorscopusid8065719600
dc.contributor.authorUlaş, Fatih
dc.contributor.authorDo?an, Ümit
dc.contributor.authorÇelik, Fatih
dc.contributor.authorŞahin, Saygin
dc.contributor.authorÇelebi, Serdal
dc.date.accessioned2024-09-25T19:43:17Z
dc.date.available2024-09-25T19:43:17Z
dc.date.issued2013
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractPurpose: To compare the retinal vascular caliber changes in diabetic macular edema patients receiving intravitreal triamcinolone acetonide and bevacizumab. Materials and Methods: Retinal vascular caliber of 42 patients with diabetic macular edema aged between 41-78 were measured before, 1 week and 4 weeks after the intravitreal injection. 21 (50.0%) patients received 2 mg/0.05 ml intravitreal triamcinolone acetonide and 21 (50.0%) patients received 1.25 mg/0.05 ml intravitreal bevacizumab. Retinal vascular caliber assessment was performed manually on retinal nerve fiber layer imaging mode scan by using semi-automated program of Spectralis optical coherence tomography. Statistical analyses of differences between retinal vascular caliber were determined using repeated measures of analysis of variance and Bonferroni adjustment. Results: Mean retinal arteriolar diameter of healthy control group, triamcinolone group, and bevacizumab group before the injection was 88.55±11.29, 87.19±10.00 and 91.67±16.69 ?m, respectively. Mean retinal venular diameter of healthy control group, triamcinolone group, and bevacizumab group before the injection was 127.00±16.91, 130.38±24.01 and 132.52±18.74 ?m, respectively. In triamcinolone group, there was statistically significant decline in retinal arteriolar and venular diameter during the study period (p values were 0.047 and <0.001, respectively). In bevacizumab group, retinal venular diameter was significantly decreased (p<0.001) but there was no significant change in retinal arteriolar diameter during the study period (p=0.209). Conclusions: In short-term, intravitreal triamcinolone acetonide led to more significant changes than intravitreal bevacizumab in retinal vascular caliber.en_US
dc.identifier.endpage264en_US
dc.identifier.issn1300-1256
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84892634712en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage259en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12520
dc.identifier.volume21en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectBevacizumaben_US
dc.subjectDiabetic macular edemaen_US
dc.subjectMacular volumeen_US
dc.subjectRetinal vascular caliberen_US
dc.subjectTriamcinolone acetonideen_US
dc.titleA comparison of short-term effects of intravitreal triamcinolone acetonide and bevacizumab on retinal vascular caliber in patients with diabetic macular edemaen_US
dc.title.alternativeDiyabetik maküler ödemi olan hastalarda intravitreal triamsinolon asetonid ve bevacizumabin retinal damar çapi üzerine kisa dönem etkilerinin karşilaştirilmasi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu